United States

Upsher-Smith announces positive data for epilepsy drug USL261

Friday, May 2, 2014 12:23 PM

Upsher-Smith Laboratories has announced positive phase I data for USL261 (investigational intranasal midazolam) in patients with epilepsy. Results demonstrated that USL261 at a single dose of up to 7.5mg was rapidly absorbed and exhibited a short half-life. Additionally, USL261 generally was well-tolerated in patients with epilepsy and demonstrated a rapid onset of pharmacodynamic effects with return to baseline function by four hours post dose.

More... »

WIRB Copernicus Group

The Buoniconti Fund, Permobil partner for mobility research awareness

Thursday, May 1, 2014 10:20 AM

Nick and Marc Buoniconti, in conjunction with the Buoniconti Fund to Cure Paralysis, the fundraising arm of the Miami Project to Cure Paralysis, have announced a partnership with Permobil, a wheelchair provider, to jointly promote mobility and paralysis research awareness.

More... »


FDA approves Zykadia for late-stage lung cancer

Wednesday, April 30, 2014 03:01 PM

The FDA has granted accelerated approval to Zykadia (ceritinib) for patients with a certain type of late-stage (metastatic) non-small cell lung cancer (NSCLC).

More... »

Wisconsin awards grant to Bridge to Cures to commercialize university R&D

Wednesday, April 30, 2014 11:32 AM

In an effort to deliver the benefits of medical discovery to patients seeking relief, the Wisconsin Economic Development Corporation (WEDC) has awarded a $140,000 grant to Bridge to Cures (B2C), a new nonprofit, to establish a new seed fund. The matching grant will enable B2C to provide seed money to entrepreneurs at academic institutions in southeastern Wisconsin seeking to translate their medical research and inventions into products and companies in the healthcare space.

More... »

Rutgers receives $26M antibiotics grant from NIH

Wednesday, April 30, 2014 11:26 AM

The National Institute of Allergy and Infectious Diseases (NIAID) of the NIH has selected infectious disease expert David Perlin, executive director of the Public Health Research Institute at Rutgers New Jersey Medical School, to lead a major research effort aimed at developing new forms of antibiotics to regain the upper hand over deadly bacteria that have become resistant to current treatments.  

More... »

Michael S. Gordon named medical director for cancer center trials at Scottsdale Healthcare

Friday, April 25, 2014 11:21 AM

Michael S. Gordon, M.D., has been named the new medical director for the Virginia G. Piper Cancer Center Clinical Trials program at Scottsdale Healthcare. Gordon will oversee the center's phase I clinical trials program. Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership with Translational Genomics Research Institute, is a clinical research site for phase I studies of new cancer drugs.

More... »

Report: Inventor incentives could spur medical innovation, cut spending

Wednesday, April 23, 2014 01:55 PM

To help rein in massive healthcare spending, a new RAND study concludes U.S. policymakers should urgently find ways to incentivize pharmaceutical companies and device makers to develop products that produce more value. RAND is a research organization that develops solutions to public policy challenges.

More... »

Scripps Florida Scientists awarded $2M for anti-diabetic drug design

Wednesday, April 23, 2014 01:46 PM

The NIH has awarded scientists from the Florida campus of The Scripps Research Institute (TSRI) $2.1 million to study the therapeutic potential of safer and more effective alternatives to the current crop of anti-diabetic drugs, which have been limited in their use due to side effects including bone loss and congestive heart failure.

More... »

GSK, Genmab receive FDA approval for Arzerra (ofatumumab) for CLL

Monday, April 21, 2014 09:27 AM

GlaxoSmithKline and Genmab have announced that the FDA has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra (ofatumumab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.

More... »

Arsenal Capital acquires Synchrogenix for regulatory writing, submission services, will merge it with Certara

Tuesday, April 15, 2014 01:11 PM

Arsenal Capital Partners, a private equity firm that acquired software and scientific consulting services provider Certara last December, now has purchased Synchrogenix, an independent regulatory-writing CRO, and will merge the two.

More... »

`
CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

August 18

Ebola outbreak highlights need to improve biosafety, infrastructure to handle future health emergencies

More African American professional women open to participating in medical research

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs